Chemotherapy-Induced Nausea and Vomiting (CINV) Clinical Trial
Official title:
Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability & Efficacy of a Single Dose of Intravenous MK0517 for Prevention of Chemotherapy-Induced Nausea & Vomiting Associated With Cisplatin Chemo
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01594749 -
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
|
Phase 3 | |
| Not yet recruiting |
NCT04912271 -
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
|
Phase 3 | |
| Active, not recruiting |
NCT05434663 -
Safety Study of Repeat Doses of SUSTOL in Adults
|
Phase 4 | |
| Recruiting |
NCT04472143 -
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
|
Phase 2 | |
| Completed |
NCT03204279 -
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 2 | |
| Completed |
NCT00952341 -
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT01111851 -
Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
|
Phase 1 |